Annexon, Inc.
tanruprubart
Guillain-Barré Syndrome (GBS)
Date
TBD
Phase 1 readout · Date TBD estimated
What's at stake
Phase 1 trial results for tanruprubart in Guillain-Barré Syndrome (GBS) are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“BLA Submission with U.S./European Data from FORWARD Trial Anticipated in 2026”